Brian M. Castellano

Brian M. Castellano

Auto-generated profile, based on publicly available information

Brian M. Castellano

Department of Biology, Massachusetts Institute of Technology

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2017 in Science
Verified
Journal Article
Closed access
PDF file
BCBrian M. Castellano
Brian M. Castellano
ATAshley M. Thelen
Ashley M. Thelen
OMOfer Moldavski
Ofer Moldavski
MFMcKenna Feltes
McKenna Feltes
RWReini E. N. van der Welle
Reini E. N. van der Welle
RZRoberto Zoncu
Roberto Zoncu
A cholesterol-mTORC1 axis may play a role in metabolic homeostasis in normal and disease states.

21 December 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JOJessica Okosun
Jessica Okosun
RWRachel L Wolfson
Rachel L Wolfson
JWJun Wang
Jun Wang
SAShamzah Araf
Shamzah Araf
LWLucy Wilkins
Lucy Wilkins
JFJude Fitzgibbon
Jude Fitzgibbon
Jessica Okosun, David Sabatini and colleagues identify recurrent RRAGC mutations in follicular lymphoma, resulting in activated mTORC1 signaling. The activating nature of the mutations, their existence within the dominant clone and their stability during disease progression support the potential of these mutations as promising candidates for targeted therapy. Follicular lymphoma is an incurable B cell malignancy1 characterized by the t(14;18) translocation and mutations affecting the epigenome2,3. Although frequent gene mutations in key signaling pathways, including JAK-STAT, NOTCH and NF-κB, have also been defined2,3,4,5,6,7, the spectrum of these mutations typically overlaps with that in the closely related diffuse large B cell lymphoma (DLBCL)6,7,8,9,10,11,12,13. Using a combination of discovery exome and extended targeted sequencing, we identified recurrent somatic mutations in RRAGC uniquely enriched in patients with follicular lymphoma (17%). More than half of the mutations preferentially co-occurred with mutations in ATP6V1B2 and ATP6AP1, which encode components of the vacuolar H+-ATP ATPase (V-ATPase) known to be necessary for amino acid−induced activation of mTORC1. The RagC variants increased raptor binding while rendering mTORC1 signaling resistant to amino acid deprivation. The activating nature of the RRAGC mutations, their existence in the dominant clone and their stability during disease progression support their potential as an excellent candidate for therapeutic targeting.

1 November 2017 in Cell Reports
Verified
Journal Article
Open access
JLJustin A. De Leon
Justin A. De Leon
JQJiazhang Qiu
Jiazhang Qiu
CNChristopher J. Nicolai
Christopher J. Nicolai
JCJessica L. Counihan
Jessica L. Counihan
KBKevin C. Barry
Kevin C. Barry
RVRussell E. Vance
Russell E. Vance
All pathogens must acquire nutrients from their hosts. The intracellular bacterial pathogen Legionella pneumophila, the etiological agent of Legionnaires' disease, requires host amino acids for growth within cells. The mechanistic target of rapamycin complex 1 (mTORC1) is an evolutionarily conserved master regulator of host amino acid metabolism. Here, we identify two families of translocated L. pneumophila effector proteins that exhibit opposing effects on mTORC1 activity. The Legionella glucosyltransferase (Lgt) effector family activates mTORC1, through inhibition of host translation, whereas the SidE/SdeABC (SidE) effector family acts as mTORC1 inhibitors. We demonstrate that a common activity of both effector families is to inhibit host translation. We propose that the Lgt and SidE families of effectors work in concert to liberate host amino acids for consumption by L. pneumophila.

17 June 2013 in The Journal of Physical Chemistry B
Verified
Journal Article
Open access
BCBrian M. Castellano
Brian M. Castellano
DEDaryl Eggers
Daryl Eggers
This study introduces a new thermodynamic framework for aqueous reaction equilibria that treats water as a coreactant in the development of a general binding equation. The approach features an explicit consideration for the change in hydration that occurs when two solvated surfaces come into contact. As an outcome of this framework, the standard-state free energy of binding is defined by the summation of two terms: the traditional term (−RT ln Ki) plus a desolvation free-energy term that is weighted by the number of complexes formed at equilibrium. The new formalism suggests that the equilibrium ratio, Ki, is not a constant and that the observed concentration dependence of Ki may be used to obtain the molar desolvation energy and the standard-state free energy at infinite dilution. The governing equation is supported by results from isothermal titration calorimetry using the chelation of calcium(II) by EDTA as a model binding reaction. This work may have far-reaching implications for solution thermodynamics, including an explanation for the oft-noted discrepancy between the enthalpy values obtained by calorimetry and those from the van’t Hoff approach.

1 August 2020 in Journal of Biotechnology
Verified
Journal Article
Closed access
SLSalina Louie
Salina Louie
JLJayanthi Lakkyreddy
Jayanthi Lakkyreddy
BCBrian M. Castellano
Brian M. Castellano
BHBenjamin Haley
Benjamin Haley
ADAnh Nguyen Dang
Anh Nguyen Dang
SMShahram Misaghi
Shahram Misaghi

19 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAndrew D. Gnann
Andrew D. Gnann
YXYuan Xia
Yuan Xia
JSJess Soule
Jess Soule
CBClara Barthélemy
Clara Barthélemy
JMJayata Mawani
Jayata Mawani
DDDaniel P. Dowling
Daniel P. Dowling
Nonribosomal peptide synthetase (NRPS) heterocyclization (Cy) domains generate biologically important ox-/thiazoline modifications in natural products, including in production of compounds targeting disease or siderophores that are important for bacterial pathogenicity. Cy domains share the NRPS condensation domain fold but catalyze consecutive condensation and cyclodehydration reactions via an unknown mechanism. To further understanding of Cy domain catalysis, we report the crystal structure of the second Cy domain (Cy2) of yersiniabactin synthetase from the causative agent of the plague, Yersinia pestis . We find the high-resolution structure of Cy2 adopts a conformation enabling exploration of binding the extended, thiazoline-containing cyclodehydration intermediate for catalysis and the acceptor carrier protein to which it is tethered. We also report complementary electrostatic interfaces between Cy2 and its donor carrier protein that mediate donor binding. Lastly, we explore domain flexibility through the normal mode approximation and identify small-molecule fragment binding sites to inform antibiotic design targeting Cy function. Our results suggest how carrier protein binding may influence global conformation, with consequences for active site catalytic states and inhibitor development.